Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:

NCT ID: NCT04973774 Recruiting - Clinical trials for Magnetic Resonance Imaging

A Multi-center Prospective Study of Branch Atheromatous Disease in China

Start date: June 1, 2021
Phase:
Study type: Observational [Patient Registry]

Branch atheromatous disease (BAD), is regarded as one of the important etiologies for acute isolated subcortical infarction, especially in Asian population. However, due to the fact that the existing imaging techniques cannot depict small vessel changes, the clinical diagnosis, therapy and research of BAD are facing challenges. We have started a multi-center prospective observational study of BAD in China, aiming at establishing a large-sample clinical-radiological cohort of BAD, analyzing predictors for functional outcome, and exploring the efficacy of tirofiban on BAD. A standardized Case Report Form (and eCRF on website) is used to collect baseline and follow-up information on epidemiological, clinical, radiological(MRI, SWI, MRA, HRMRI,3TVWI)and blood test. The primary outcome was mRS on 90 days with blind evaluation.

NCT ID: NCT04950972 Recruiting - Clinical trials for Large Hemispheric Infarction (LHI)

Intravenous Administration of BIIB093 (Glibenclamide) in the Treatment of Severe Cerebral Edema After Massive Cerebral Infarction

Start date: September 1, 2020
Phase: Phase 3
Study type: Interventional

The current study is to assess efficacy and safety of intravenous (IV) BIIB093 to improve functional outcomes in subjects with LHI.

NCT ID: NCT04950790 Recruiting - Clinical trials for Acute Ischemic Stroke

Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke

Start date: April 1, 2018
Phase: Phase 4
Study type: Interventional

This is a randomized, double-blind, placebo-parallel-controlled multiplier designed to observe and evaluate the efficacy and safety of Shuxuening injection in the treatment of acute ischemic stroke for 10 days and continue follow-up to 90 days after the onset of the disease.

NCT ID: NCT04938479 Recruiting - Cerebral Infarction Clinical Trials

D-dimer Prognostic Marker of Cerebral Infarction After Revascularization Procedure

D-Dimer
Start date: June 15, 2021
Phase:
Study type: Observational

Cerebral infarction is the leading cause of acquired disability in adults. Absence of biological marker used in current practice and identified as a prognostic factor for recovery. D-dimers are degradation products of stabilized fibrin translating an activation of coagulation whatever the cause. Studies have shown that increased D-dimer levels in patients with MI is associated with a higher mortality rate, the link with post-intervention non-revascularization has been demonstrate. The purpose of this project is to search for a correlation between the level of D-dimer and the degree of recovery evaluated by the NIHSS score

NCT ID: NCT04916782 Recruiting - Clinical trials for Acute Ischemic Stroke

Evaluation of Functional Recovery of Patients With Acute Ischemic Stroke Treated by Thrombectomy

EPIC
Start date: April 28, 2022
Phase:
Study type: Observational

The management of cerebral infarctions (CI) is a real public health issue. The French National Authority for Health recommends Mechanical Thrombectomy (MT) either in combination with Intravenous Thrombolysis (IVT), or alone, after failure of IVT or in case of contraindication to IVT, within 6 hours of the onset of symptoms. The objective is to determine the factors predicting good functional recovery at 3 months in order to establish the typical profile of the "good responder" patient to MT and to evaluate functional recovery at 3 and 12 months (mRS ≤ 2) according to the modality of MT (depending on whether it is performed during the day or at night), the age of the patients, the equipment used for MT, the type of anaesthesia, as well as the impact of the metrics from the radiological evaluation in the patient's management. patient management.

NCT ID: NCT04910256 Recruiting - Ischemic Stroke Clinical Trials

Investigation of Huatuo Zaizao Pill in Treating Phlegm and Blood-stasis Blocking Collaterals Pattern of Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Trial

Start date: June 1, 2021
Phase: Phase 3
Study type: Interventional

This study is aiming to evaluate the efficacy and safety of Huatuo Zaizao pill in ischemic stroke patients who diagnosed as the phlegm and blood-stasis blocking collaterals syndrome in TCM. A total of 80 subjects will be randomly assigned to Huatuo Zaizao pill group or the control group.

NCT ID: NCT04910217 Recruiting - Ischemic Stroke Clinical Trials

Robot-Assisted Gait Therapy in the Subacute Phase of First Ischemic Stroke

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Robot-assisted gait training (RAGT) represents a modern concept of neurorehabilitation in stroke patients. This single-center randomized parallel-group neurorehabilitation trial with blinded primary outcome assessment is aimed at patients after the first-ever ischaemic stroke in the anterior or posterior cerebral circulation.

NCT ID: NCT04908241 Recruiting - Stroke Clinical Trials

Telerehabilitation With Aims to Improve Lower Extremity Recovery Post-Stroke (TRAIL-RCT)

TRAIL-RCT
Start date: November 8, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the effectiveness of a 4-week lower extremity telerehabilitation protocol with aims to improve lower extremity function to a 4-week attention-controlled education program on lower extremity clinical outcomes, quality of life, and healthcare resources utilization among community dwelling adults with stroke across Canada.

NCT ID: NCT04904172 Recruiting - Ischemic Stroke Clinical Trials

Effectiveness of NIRS (Near-Infrared Spectroscopy) at Acute Ischemic Stroke Patients

Start date: November 1, 2020
Phase:
Study type: Observational [Patient Registry]

Near-infrared spectroscopy (NIRS) is a non-invasive technology that continuously monitors regional tissue oxygenation (tissue saturation with oxygen). NIRS is used to evaluate the oxygen saturation of the brain and other tissues (such as muscle, liver, lung). NIRS is a non-invasive, simple, bedside method that can be used safely in stroke patients, as it is a method that can be performed at the bedside and does not affect the treatment process. The NIRS, which we will use in our study, continuously measures with the help of two electrodes affixed to the forehead area, right and left. There are previously created scales and scales based on neurological examination in the follow-up of patients with acute ischemic stroke. The main ones are the Glasgow Coma Scale (GCS), which is used without evaluating the patient's consciousness; It is the National Institutes of Health Stroke Scale (NIHSS), which is used to evaluate the severity of ischemic stroke, its suitability for treatment and treatment response, and the Modified Rankin Scale (mRS), which is used to evaluate the daily activity ability of individuals. However, since these cannot predict the patient's response to treatment and complications that will develop early, and there are no objective parameters, there is a need for methods that require objective monitoring of the patients. Acute ischemic stroke patients who received intravenous thrombolytic therapy with NIRS and / or who underwent endovascular thrombectomy are monitored for 24 hours and the data obtained from this method are compared with the vital findings, GCS, NIHSS, mRS, which are traditionally used in the follow-up of these patients. Thus, it was aimed to evaluate the utility of this method in evaluating the treatment efficacy and prognosis of patients compared to traditional methods in acute ischemic stroke patients.

NCT ID: NCT04892511 Recruiting - Clinical trials for Acute Ischemic Stroke

Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke

HOPE
Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Mechanical thrombectomy is a very effective treatment in patients who have suffered an acute ischemic stroke associated with intracranial large vessel occlusion. However, less than half of the patients achieve functional independence despite treatment. The optimization of blood pressure after mechanical thrombectomy based on the degree of recanalization achieved at the end of the procedure could improve the perfusion of the ischemic brain tissue thanks to the improvement of blood circulation provided by collateral circulation. For this, authorized hypotensive or hypertensive drugs will be used. Moreover, this individualized treatment would allow to decrease reperfusion injury and therefore decrease the risk of intracerebral bleeding complications and cerebral edema. Therefore, we designed a clinical trial in which the standard management of blood pressure after mechanical thrombectomy will be compared with a specific protocol in which blood pressure targets are applied according to the degree of recanalization obtained during the thrombectomy procedure. The beneficial effect and risk reduction of this treatment will translate into a better short and long-term outcome